PEDEvidence

P021

What it is & what research shows

Study example available

P021 is a CNTF-derived peptidergic research compound. It is distinct from the p21/CDKN1A protein and from products identified only by the ambiguous label P21. The research below distinguishes observed findings from interpretation. [1.1]

Selected animal research: Female transgenic Alzheimer-model and wild-type mice received P021 or vehicle diet for 12 months, beginning at 9–10 months of age. Dose and sample size are not stated in the abstract. Treatment reduced abnormal tau changes and soluble amyloid-beta and improved measured cognition and synaptic plasticity. Plaque reduction was a trend rather than a demonstrated significant effect. Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation. Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation. A verified studied dose has not yet been added to this reading note. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal.
Sources & reading scope

Study-summary coverage

No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.

Filter, save and compare P021 studies →

Selected study reading notes

Source-linked summaries with studied methods. These are separate from the automated summary counts above and are not formal quality appraisals.

Animal

P021: what does this study show?

Female transgenic Alzheimer-model and wild-type mice received P021 or vehicle diet for 12 months, beginning at 9–10 months of age. Dose and sample size are not stated in the abstract.

Demonstrated findings

Treatment reduced abnormal tau changes and soluble amyloid-beta and improved measured cognition and synaptic plasticity. Plaque reduction was a trend rather than a demonstrated significant effect.

Limitations & adverse findings

Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation.

What might this mean? · interpretation

These findings apply to the population and methods described above.

What might this mean, and what would change the interpretation?

Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation.

What would clarify this: Controlled human safety and efficacy research would be needed before clinical conclusions.

Findings reviewed · abstract

Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

More about P021: identity, safety & reference details
PeptideBrain & cognition
Primary research area
Neurological & cognitive research
Regulatory status
See compound-specific sources
Evidence level
Animal · preclinical research
Primary mechanism
See the source-linked compound overview
Reference profile available · Coverage varies by section

Also known as Peptide 021 · P-021

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Animal · Abstract reviewed

P021: what does this study show?

Female transgenic Alzheimer-model and wild-type mice received P021 or vehicle diet for 12 months, beginning at 9–10 months of age. Dose and sample size are not stated in the abstract.

Treatment reduced abnormal tau changes and soluble amyloid-beta and improved measured cognition and synaptic plasticity. Plaque reduction was a trend rather than a demonstrated significant effect.

Limits & adverse findings: Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation. Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation.

Open primary source · Read interpretation separately
Explore outcomes for this compound
Uses & research

The research below distinguishes observed findings from interpretation. [1]

Known half-life

No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.

Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits

Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation. [1]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation.

Animal study: Mouse disease-model findings do not establish human benefit or a human dose. The proposed BDNF pathway explanation remains mechanistic interpretation. Source

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: P021 · p021

Searchable names: Peptide 021, P-021

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

CNTF-derived peptidergic compound. Kept distinct from the p21/CDKN1A protein and ambiguous P21 product labels.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

  1. 1. Chronic oral P021 in a transgenic Alzheimer mouse model Animal · primary publication abstract

Reference facts checked 2026-09-23. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…